PMID- 36452225
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221202
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: A 
      systematic review and meta-analysis of 42 randomized controlled trials.
PG  - 1002713
LID - 10.3389/fphar.2022.1002713 [doi]
LID - 1002713
AB  - Objective: Patients with stable coronary artery disease (SCAD) still have a 
      higher risk of adverse cardiovascular events. Shexiang Baoxin Pill (SBP) is 
      widely used as a complementary and alternative treatment for SCAD. This study 
      aimed to further verify the therapeutic effect and safety of SBP on SCAD. 
      Methods: Seven databases were involved in this meta-analysis as of 1 June 2022. 
      Data was collected from all the randomized controlled trials (RCTs) of the 
      combination of SBP and conventional western medicine (CWM) in treating SCAD which 
      was conducted by two independent authors. Risk of bias was assessed using the 
      Cochrane risk-of-bias 2.0 (RoB2.0) tool, and the meta-analysis was accomplished 
      with Review Manager 5.3. Furthermore, the Grading of Recommendations Assessment, 
      Development and Evaluation (GRADE) profiler 3.2.2 software was selected to grade 
      the current evidence in our findings. Results: 42 articles, involving 6,694 
      patients were screened among all the 1,374 records in the analysis. The results 
      demonstrated that the combination therapy was more efficient than CWM alone in 
      lowering the incidence of major adverse cardiovascular events (MACE, RR = 0.50, 
      95% CI: 0.37 to 0.68, p < 0.00001) and ameliorating the total effective rate of 
      angina symptom improvement (RR = 1.23, 95% CI: 1.19 to 1.28, p < 0.00001), the 
      effective rate of electrocardiogram improvement (RR = 1.34, 95% CI: 1.26 to 1.43, 
      p < 0.00001), the frequency of angina pectoris (MD = -2.83, 95% CI: -3.62 to 
      -2.05, p < 0.00001), and the duration of angina pectoris (MD = -1.32, 95% CI: 
      -2.04 to -0.61, p = 0.0003). We also found that, after SBP treatment, a more 
      positive blood lipid level and left ventricular ejection fraction without the 
      increase in adverse cases were calculated in our meta-analysis. What's more, 
      Subgroup analysis indicated that treatment duration may be the source of 
      heterogeneity. The certainty of the evidence for MACE, and electrocardiogram 
      improvement exhibited moderate certainty, and the certainty of the evidence for 
      the remaining outcomes was judged as low certainty. The trial sequential analysis 
      further affirmed the clinical efficacy of SBP. Conclusion: The available evidence 
      indicates that SBP may be an effective therapeutic option in patients with SCAD. 
      However, considering the inferior quality and inconsistent results in the 
      included trials, further rigorous RCTs are required. Systematic Review 
      Registration: https://www.crd.york.ac.uk/prospero, identifier [CRD42022334529].
CI  - Copyright (c) 2022 Wei, Ma, Zhou, Hao, Li, Wang, Yu, Zhu and Wang.
FAU - Wei, Jingjing
AU  - Wei J
AD  - The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 
      Henan, China.
AD  - Department of Cardiovascular Diseases, The First Affiliated Hospital of Henan 
      University of Chinese Medicine, Zhengzhou, Henan, China.
FAU - Ma, Teng
AU  - Ma T
AD  - Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China.
FAU - Zhou, Cheng
AU  - Zhou C
AD  - The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 
      Henan, China.
FAU - Hao, Pengle
AU  - Hao P
AD  - The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 
      Henan, China.
FAU - Li, Bin
AU  - Li B
AD  - Department of Cardiovascular Diseases, The First Affiliated Hospital of Henan 
      University of Chinese Medicine, Zhengzhou, Henan, China.
FAU - Wang, Xinlu
AU  - Wang X
AD  - Department of Cardiovascular Diseases, The First Affiliated Hospital of Henan 
      University of Chinese Medicine, Zhengzhou, Henan, China.
FAU - Yu, Rui
AU  - Yu R
AD  - Department of Cardiovascular Diseases, The First Affiliated Hospital of Henan 
      University of Chinese Medicine, Zhengzhou, Henan, China.
FAU - Zhu, Mingjun
AU  - Zhu M
AD  - Department of Cardiovascular Diseases, The First Affiliated Hospital of Henan 
      University of Chinese Medicine, Zhengzhou, Henan, China.
FAU - Wang, Yongxia
AU  - Wang Y
AD  - Department of Cardiovascular Diseases, The First Affiliated Hospital of Henan 
      University of Chinese Medicine, Zhengzhou, Henan, China.
LA  - eng
PT  - Systematic Review
DEP - 20221114
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9701736
OTO - NOTNLM
OT  - Shexiang Baoxin Pill
OT  - grade
OT  - meta-analysis
OT  - randomized controlled trials
OT  - stable coronary artery disease
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/02 06:00
MHDA- 2022/12/02 06:01
PMCR- 2022/11/14
CRDT- 2022/12/01 02:40
PHST- 2022/07/25 00:00 [received]
PHST- 2022/10/31 00:00 [accepted]
PHST- 2022/12/01 02:40 [entrez]
PHST- 2022/12/02 06:00 [pubmed]
PHST- 2022/12/02 06:01 [medline]
PHST- 2022/11/14 00:00 [pmc-release]
AID - 1002713 [pii]
AID - 10.3389/fphar.2022.1002713 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Nov 14;13:1002713. doi: 10.3389/fphar.2022.1002713. 
      eCollection 2022.